CD26/DPP-4 in Chronic Myeloid Leukemia.
Anna SicuranzaDonatella RaspadoriMonica BocchiaPublished in: Cancers (2022)
CD26 expression is altered in many solid tumors and hematological malignancies. Recently, it has been demonstrated that it is a specific marker expressed on LSCs of CML, both in BM and PB samples, and absent on CD34+/CD38- stem cells in normal subjects or on LSCs of other myeloid neoplasms. CD26+ LSCs have been detected by flow-cytometry assays in all PB samples of Chronic-Phase CML patients evaluated at diagnosis. Additionally, it has been demonstrated that most CML patients undergoing Tyrosine Kinase Inhibitors (TKIs) treatment still harbored circulating measurable residual CD26+ LSCs, even when displaying a consistent deep molecular response without any significant association among the amounts of BCR-ABL transcript and CD26+ LSCs. Preliminary data of our Italian prospective multicenter study showed that CML patients with a poorer response presented with a higher number of CD26+ LSCs at diagnosis. These data confirmed that CD26 is a specific marker of CML and suggest that it could be considered for the monitoring of therapeutic responses.
Keyphrases
- chronic myeloid leukemia
- stem cells
- nk cells
- poor prognosis
- bone marrow
- immune response
- machine learning
- ejection fraction
- tyrosine kinase
- big data
- deep learning
- high throughput
- dendritic cells
- prognostic factors
- artificial intelligence
- newly diagnosed
- long non coding rna
- single cell
- combination therapy
- replacement therapy
- cell therapy